Overview

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

Status:
Completed
Trial end date:
2017-07-12
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blind, Placebo Controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome
Phase:
Phase 3
Details
Lead Sponsor:
ICStudy, LLC
Collaborator:
UCB Pharma
Treatments:
Certolizumab Pegol